Table 2.
Effect of paricalcitol on calcium metabolism, blood pressure and 24-h albumin excretion in patients with stage III-IV CKD and albuminuria (n = 26)
| Placebo | Paricalcitol | P value | |
|---|---|---|---|
|
Calcium and phosphate metabolism | |||
| p-iPTH (pmol/l) |
11.80 [8.82;14.93] |
6.44 [3.11;8.78] |
<0.001 |
| p-Ca++ (mmol/l) |
1.22 [1.16;1.25] |
1.23 [1.19;1.28] |
0.01 |
| p-phosphate (mmol/l) |
1.18 [0.97;1.35] |
1.29 [1.10;1.59] |
0.02 |
| p-ALP (U/l) |
66 [58;91] |
65 [51;82] |
<0.001 |
| p-25(OH)D (nmol/l) |
58 [39;72] |
59 [50;69] |
0.26 |
| p-FGF23 (pg/ml) |
28.5 [19.7;46.7] |
32.3 [27.2;67.1] |
0.002 |
| u-Ca (mmol/24-h) |
0.78 [0.39;2.03] |
1.24 [0.66;3.04] |
0.006 |
| u-Ca/cr (mmol/mmol) |
0.06 [0.03;0.15] |
0.12 [0.06;0.22] |
0.005 |
|
24-h ambulatory blood pressure and arterial stiffness | |||
| 24-h SBP (mmHg) |
133 ± 11 |
133 ± 10 |
0.92 |
| 24-h DBP (mmHg) |
81 ± 7 |
81 ± 7 |
0.94 |
| 24-h heart rate (bpm) |
67 ± 9 |
68 ± 9 |
0.15 |
| PWV (m/s) |
7.9 ± 1.3 |
7.6 ± 1.3 |
0.21 |
| AIx@75 (%) |
21 ± 13 |
19 ± 11 |
0.30 |
| Central SBP (mmHg) |
132 ± 12 |
130 ± 13 |
0.34 |
| Central DBP (mmHg) |
82 ± 7 |
82 ± 6 |
0.97 |
|
Creatinine clearance and albumin excretion in 24-h urine | |||
| Urine output (ml/24-h) |
2805 [2430;3160] |
2794 [2270;3210] |
0.43 |
| Creatinine clearance (ml/min/1.73 m2) |
36 [28;51] |
32 [27;46] |
0.005 |
| u-alb (mg/24-h) |
665 [80;2598] |
590 [146;2025] |
0.12 |
| UACR (mg/g) | 507 [80;1523] | 388 [104;1109] | 0.34 |
Values are presented as medians with 25 and 75 percentiles in brackets, or as means ± SD. iPTH Intact parathyroid hormone, Ca++ Ionized calcium, ALP Alkaline phosphatase 25(OH)D, 25-hydroxyvitamin D; FGF23, fibroblast growth factor 23; u-Ca/cr, urinary calcium-creatinine ratio; PWV, carotid-femoral pulse wave velocity; AIx@75, central augmentation index standardized to a heart rate of 75 beats per minute (bpm); UACR, urinary albumin-creatinine ratio. P values represent the probability of a difference between treatments.